NYSE:TAK

Takeda Pharmaceutical (TAK) Stock Forecast, Price & News

$15.34

+0.05 (+0.33%)

(As of 08/11/2023 08:49 PM ET)

Compare

Today's Range: $15.25
▼
$15.35
50-Day Range: $15.12
▼
$16.36
52-Week Range: $12.28
▼
$17.15

Volume: 2.02 million shs
Average Volume: 2.45 million shs
Market Capitalization: $48.55 billion

P/E Ratio: 21.31
Dividend Yield: 3.32%
Price Target: $25.00

Takeda Pharmaceutical MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 63.0% Upside
$25.00 Price Target
Short Interest: Healthy
0.23% of Float Sold Short
Dividend Strength: Weak
Based on Four Factors
Sustainability: N/A
News Sentiment: 0.85
Based on 5 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.69 out of 5 stars

Medical Sector

102nd out of 988 stocks

Pharmaceutical Preparations Industry

34th out of 459 stocks

3.5

Analyst's Opinion

Consensus Rating
Takeda Pharmaceutical has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $25.00, Takeda Pharmaceutical has a forecasted upside of 63.0% from its current price of $15.34.
Amount of Analyst Coverage
Takeda Pharmaceutical has received no research coverage in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.23% of the float of Takeda Pharmaceutical has been sold short.
Short Interest Ratio / Days to Cover
Takeda Pharmaceutical has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Takeda Pharmaceutical has recently decreased by 11.04%, indicating that investor sentiment is improving significantly.

1.7

Dividend Strength

Dividend Yield
Takeda Pharmaceutical pays a meaningful dividend of 3.30%, higher than the bottom 25% of all stocks that pay dividends.
Dividend Growth
Takeda Pharmaceutical does not have a long track record of dividend growth.
Dividend Coverage
The dividend payout ratio of Takeda Pharmaceutical is 70.83%. This payout ratio is at a healthy, sustainable level, below 75%.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for TAK.

3.2

News and Social Media Coverage

News Sentiment
Takeda Pharmaceutical has a news sentiment score of 0.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Takeda Pharmaceutical this week, compared to 5 articles on an average week.
Search Interest
10 people have searched for TAK on MarketBeat in the last 30 days. This is an increase of 900% compared to the previous 30 days.
MarketBeat Follows
3 people have added Takeda Pharmaceutical to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Takeda Pharmaceutical insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 0.04% of the stock of Takeda Pharmaceutical is held by insiders.
Percentage Held by Institutions
Only 2.72% of the stock of Takeda Pharmaceutical is held by institutions.

1.9

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Takeda Pharmaceutical is 21.31, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 125.16.
Price to Earnings Ratio vs. Sector
The P/E ratio of Takeda Pharmaceutical is 21.31, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 146.80.
Price to Earnings Growth Ratio
Takeda Pharmaceutical has a PEG Ratio of 6.36. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Takeda Pharmaceutical has a P/B Ratio of 0.96. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Takeda Pharmaceutical (NYSE:TAK) Stock

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, JCR Pharmaceuticals, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.

TAK Price History

30 days | 90 days | 365 days | Advanced Chart

TAK Stock News Headlines

August 8, 2023 | finance.yahoo.com

Q3 2023 Arrowhead Pharmaceuticals Inc Earnings Call

August 8, 2023 | finance.yahoo.com

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q3 2023 Earnings Call Transcript

August 14, 2023 | Chaikin Analytics (Ad)

Wall Street Insider Makes Prediction about Hot A.I. Stock

50-year Wall Street Veteran Marc Chaikin just detailed why he's avoiding NVDA and buying this overlooked A.I. stock instead. Learn more here.

August 7, 2023 | technews.tmcnet.com

Voyager Therapeutics Announces Appointment of Beth Shafer as Chief Business Officer

July 31, 2023 | benzinga.com

Diabetes Drugs Market Size To Surpass USD 1,18,000 Million By 2032

July 27, 2023 | finance.yahoo.com

Japan's Takeda beats Q1 profit estimates on mainstay drugs, dengue vaccine

July 27, 2023 | finance.yahoo.com

The New England Journal of Medicine Publishes Data from Phase 2 Study of First Oral Orexin Receptor 2 Agonist TAK-994 in Patients with Narcolepsy Type 1

July 25, 2023 | finanznachrichten.de

KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals Expands Senior Leadership Team with Appointment of Nicole Sweeny as Chief Commercial Officer

August 14, 2023 | Chaikin Analytics (Ad)

Wall Street Insider Makes Prediction about Hot A.I. Stock

50-year Wall Street Veteran Marc Chaikin just detailed why he's avoiding NVDA and buying this overlooked A.I. stock instead. Learn more here.

July 25, 2023 | finance.yahoo.com

KalVista Pharmaceuticals Expands Senior Leadership Team with Appointment of Nicole Sweeny as Chief Commercial Officer

July 25, 2023 | marketwatch.com

Takeda Pharmaceutical Expected to Post 8.1% Rise in First-Quarter Net Profit -- Earnings Preview

July 21, 2023 | msn.com

Digitalization could be the answer to better health care for patients. But first, they need to trust it

July 17, 2023 | finance.yahoo.com

Irritable Bowel Syndrome Market to Exhibit Growth at a CAGR of 9.3% During the Study Period (2019-2032), Estimates DelveInsight

July 13, 2023 | msn.com

Nvidia Just Confirmed an Emerging AI Boom in Biotech

July 11, 2023 | finance.yahoo.com

Takeda withdraws application for dengue vaccine candidate

July 11, 2023 | reuters.com

Takeda withdraws US application for dengue vaccine candidate

July 11, 2023 | finance.yahoo.com

UPDATE 1-Takeda withdraws US application for dengue vaccine candidate

July 5, 2023 | news.yahoo.com

China extends squeezed-out foreign pharmaceuticals firms an olive branch

July 4, 2023 | finance.yahoo.com

Chemotherapy Global Market Report 2023

July 4, 2023 | finance.yahoo.com

Quit Smoking Drugs Global Market Report 2023

June 29, 2023 | msn.com

Takeda Warns New Drugs at Risk If Countries Push Deep Price Cuts

June 27, 2023 | markets.businessinsider.com

Grabar Law Office Investigates Claims on Behalf of Shareholders of Shattuck Labs, Inc. (STTK) After Class Action Settlement Is Preliminarily Approved

June 27, 2023 | news.yahoo.com

AI-made drug starts human trials

June 25, 2023 | finance.yahoo.com

Pivotal Phase 3 Data Presented at ISTH 2023 Congress Spotlight TAK-755 Prophylaxis for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

June 21, 2023 | finance.yahoo.com

ADHD Medication Shortage Worsens, Vyvanse Supply Dwindles Amid Adderall Scarcity

June 20, 2023 | finance.yahoo.com

Takeda Presents Full Data Set from Phase 3 ADVANCE-CIDP 1 Clinical Trial Investigating HYQVIA® as a Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting

June 16, 2023 | seekingalpha.com

TAK Takeda Pharmaceutical Company Limited

See More Headlines

Receive TAK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Takeda Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

TAK Company Calendar

Today: 8/13/2023
Next Earnings (Estimated): 10/26/2023
Fiscal Year End: 3/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NYSE:TAK
CUSIP: N/A
CIK: 1395064
Web: www.takeda.com
Phone: (166) 204-2111
Fax: 813-3278-2268
Employees: 49,095
Year Founded: 1781

Price Target and Rating

Average Stock Price Forecast: $25.00
High Stock Price Forecast: $30.00
Low Stock Price Forecast: $20.00
Forecasted Upside/Downside: +63.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): $0.72
Trailing P/E Ratio: 21.31
Forward P/E Ratio: 40.37
P/E Growth: 6.36
Net Income: $2.35 billion
Net Margins: 7.34%
Pretax Margin: 8.38%
Return on Equity: 12.54%
Return on Assets: 5.77%

Debt

Debt-to-Equity Ratio: 0.63
Current Ratio: 0.99
Quick Ratio: 0.56

Sales & Book Value

Annual Sales: $29.81 billion
Price / Sales: 1.63
Cash Flow: $3.58 per share
Price / Cash Flow: 4.28
Book Value: $15.97 per share
Price / Book: 0.96

Miscellaneous

Outstanding Shares: 3,164,660,000
Free Float: 3,163,390,000
Market Cap: $48.55 billion
Optionable: Optionable
Beta: 0.62

Social Links

(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

Mr. Christophe Weber (Age 57)
Pres, CEO & Representative Director
Comp: $3.98M

Mr. Constantine Saroukos (Age 52)
CFO & Representative Director
Comp: $2.48M

Dr. Andrew S. Plump (Age 58)
Pres of R&D and Representative Director
Comp: $2.84M

Dr. Seigo Izumo
Chair of Management Board

Mr. Haruhiko Hirate (Age 66)
Member of Management Board

Salvatore Alesci
Member of Management Board and Head of R&D Global Science & Biomedical Policy

Norimasa Takeda
Chief Accounting Officer & Corp. Controller

Mr. Iwaaki Taniguchi
Sr. VP of Corp. Fin. & Controlling Department

Mr. Gabriele Ricci (Age 45)
Chief Data & Technology Officer

Mr. Christopher David O'Reilly
Global Head of Investor Relations & Global Fin.

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

TAK Stock - Frequently Asked Questions

Should I buy or sell Takeda Pharmaceutical stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Takeda Pharmaceutical in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" TAK shares.
View TAK analyst ratings or view top-rated stocks.
What is Takeda Pharmaceutical's stock price forecast for 2023?: 2 brokerages have issued 1 year price targets for Takeda Pharmaceutical's stock. Their TAK share price forecasts range from $20.00 to $30.00. On average, they expect the company's share price to reach $25.00 in the next twelve months. This suggests a possible upside of 63.0% from the stock's current price.
View analysts price targets for TAK or view top-rated stocks among Wall Street analysts.
How have TAK shares performed in 2023?: Takeda Pharmaceutical's stock was trading at $15.60 at the beginning of the year. Since then, TAK stock has decreased by 1.7% and is now trading at $15.34.
View the best growth stocks for 2023 here.
When is Takeda Pharmaceutical's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, October 26th 2023.
View our TAK earnings forecast.
What ETFs hold Takeda Pharmaceutical's stock?: ETFs with the largest weight of Takeda Pharmaceutical (NYSE:TAK) stock in their portfolio include VanEck Pharmaceutical ETF (PPH), ActivePassive International Equity ETF (APIE), B.A.D. Etf (BAD) and First Trust International IPO ETF (FPXI).ETFMG Treatments Testing and Advancements ETF (GERM).
Is Takeda Pharmaceutical a good dividend stock?: Takeda Pharmaceutical (NYSE:TAK) pays an annual dividend of $0.51 per share and currently has a dividend yield of 3.30%. The dividend payout ratio is 70.83%. This payout ratio is at a healthy, sustainable level, below 75%.
What guidance has Takeda Pharmaceutical issued on next quarter's earnings?: Takeda Pharmaceutical issued an update on its FY 2023 earnings guidance on Thursday, July, 27th. The company provided earnings per share (EPS) guidance of $3.16-$3.16 for the period. The company issued revenue guidance of $27.99 billion-$27.99 billion.
What other stocks do shareholders of Takeda Pharmaceutical own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Takeda Pharmaceutical investors own include Cisco Systems (CSCO), Johnson & Johnson (JNJ), Alibaba Group (BABA), Pfizer (PFE), Verizon Communications (VZ), AbbVie (ABBV), CVS Health (CVS), Gilead Sciences (GILD), AT&T (T) and Abbott Laboratories (ABT).

What is Takeda Pharmaceutical's stock symbol?: Takeda Pharmaceutical trades on the New York Stock Exchange (NYSE) under the ticker symbol "TAK."
Who are Takeda Pharmaceutical's major shareholders?: Takeda Pharmaceutical's stock is owned by many different retail and institutional investors. Top institutional investors include Capital Research Global Investors (0.44%), Renaissance Technologies LLC (0.12%), Clal Insurance Enterprises Holdings Ltd (0.09%), BlackRock Inc. (0.08%), Y.D. More Investments Ltd (0.05%) and Envestnet Asset Management Inc. (0.05%).
How do I buy shares of Takeda Pharmaceutical?: Shares of TAK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Takeda Pharmaceutical's stock price today?: One share of TAK stock can currently be purchased for approximately $15.34.
How much money does Takeda Pharmaceutical make?: Takeda Pharmaceutical (NYSE:TAK) has a market capitalization of $48.55 billion and generates $29.81 billion in revenue each year. The company earns $2.35 billion in net income (profit) each year or $0.72 on an earnings per share basis.
How many employees does Takeda Pharmaceutical have?: The company employs 49,095 workers across the globe.
Does Takeda Pharmaceutical have any subsidiaries?: The following companies are subsidiares of Takeda Pharmaceutical: ARIAD Pharmaceuticals, Baxalta Manufacturing S.à r.l., IDM Pharma Inc., Intellikine, Inviragen, LigoCyte Pharmaceuticals, Meritage Pharma Inc., Millennium Pharmaceuticals, Millennium Pharmaceuticals Inc., Nihon Pharmaceutical Co. Ltd., Nycomed Pharma, PvP Biologics, Shire, Shire ViroPharma LLC, Takeda (China) Holdings Co. Ltd., Takeda AS, Takeda Austria GmbH, Takeda Bio Development Center, Takeda California Inc., Takeda Consumer Healthcare Company Limited, Takeda Development Center Americas Inc., Takeda Development Center Asia Pte. Ltd., Takeda Development Centre Europe Ltd., Takeda Distribuidora Ltda., Takeda France S.A.S., Takeda GmbH, Takeda Ireland Limited, Takeda Italia S.p.A., Takeda Pharma A/S, Takeda Pharmaceutical (China) Company Limited, Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals Korea Co. Ltd., Takeda Pharmaceuticals Limited Liability Company, Takeda Pharmaceuticals U.S.A. Inc., Takeda UK Limited, Takeda Vaccines Inc., Takeda Vaccines Pte. Ltd., and TiGenix.
Read More
How can I contact Takeda Pharmaceutical?: Takeda Pharmaceutical's mailing address is 1-1 NIHONBASHI-HONCHO 2-CHOME CHUO-KU, TOKYO M0, 103-8668. The official website for the company is www.takeda.com. The company can be reached via phone at (166) 204-2111, via email at takeda.ir.contact@takeda.com, or via fax at 813-3278-2268.

This page (NYSE:TAK) was last updated on 8/14/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial